FDA Committee Unanimously Supports CAR-T Therapies for Multiple Myeloma Despite Early Death Risks
Silver Spring, Maryland – The FDA’s Oncologic Drugs Advisory Committee voted in favor of supporting the approvals of CAR-T therapies as earlier lines of treatment for multiple myeloma. Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio’s therapies were discussed during the meeting, with a focus on the risks associated with early deaths in … Read more